（文章来源：证券日报） 证券日报网讯 2月3日，华特达因在互动平台回答投资者提问时表示，近一年来公司子公司达因药业获 得了丙戊酸钠口服溶液和盐酸可乐定缓释片的药品注册证书，在研产品异丙托溴铵吸入气雾剂获批开展 临床试验。公司将持续聚焦儿童医药健康主业，以儿童临床需要和营养健康需求为导向，秉承"量身定 制儿童药物"和"质量源于设计"的研发理念，重点开展精神、呼吸、消化等领域研发，通过研发平均每 年推出1-2种儿童专用药物，不断丰富和完善公司儿童用药产品体系，提升核心竞争力。 ...

Core Viewpoint - The company, Watson, has received approval from the National Medical Products Administration for a clinical trial of a new drug, indicating a significant step in its product development pipeline [1] Group 1: Drug Approval - Watson's subsidiary, Dain Pharmaceutical, has been granted a "Drug Clinical Trial Approval Notice" for the drug named Isopropyl Bromide Inhalation Aerosol [1] - The drug is classified as a Class 4 chemical drug and is intended for the prevention and treatment of respiratory difficulties associated with chronic obstructive airway diseases, chronic bronchitis with or without emphysema, and mild to moderate bronchial asthma in both children and adults [1] Group 2: Next Steps - Following the approval of the clinical trial, the company must conduct clinical trials before applying for production and market approval from the National Medical Products Administration [1]